Rivaroxaban Market Size, Share, and Industry Analysis, By Product (Xarelto and Others), By Strength (2.5 mg, 10 mg, 15 mg, 20 mg, and 1 mg/mL), By Dosage Form (Tablets and Oral Suspension), By Type (Branded and Generic), By Disease Indication (Deep Vein Thrombosis, Pulmonary Embolism, Coronary Artery Disease, Peripheral Artery Disease, Thromboprophylaxis, and Others), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies), and Regional Forecast till 2034

The global rivaroxaban market was valued at USD 8.50 billion in 2025. The market is projected to grow from USD 7.90 billion in 2026 to USD 8.75 billion by 2034, exhibiting a CAGR of 1.3% during the forecast period.

The market is mature and commercially important, driven by the rising need for oral therapies that help prevent and treat blood clots across cardiovascular and thromboembolic conditions. Rivaroxaban is widely used for deep vein thrombosis, pulmonary embolism, coronary artery disease, peripheral artery disease, thromboprophylaxis, and selected pediatric clot-prevention indications, which expands its use across hospitals, cardiology clinics, retail pharmacies, and long-term outpatient care. Xarelto has historically led the market. Still, the entry of FDA-approved generic rivaroxaban tablets in 2025 is increasing price competition and improving patient access, causing the market to shift from a predominantly branded structure toward a mixed branded-and-generic market.

• For instance, in August 2025, Indoco Remedies announced that it received final ANDA approval from the U.S. FDA for Rivaroxaban Tablets USP in 2.5 mg, 10 mg, 15 mg, and 20 mg strengths. This approval strengthened the generic rivaroxaban market as it added another multi-strength supplier for a generic equivalent to Janssen’s Xarelto, improving availability across major adult anticoagulation indications such as CAD, PAD, DVT, PE, and thromboprophylaxis.

Furthermore, new product launches, pipeline expansion, and partnerships by key operating companies strengthen their market position and support global market growth.

Rivaroxaban Market Driver

Rising Burden of Cardiovascular and Thromboembolic Disorders to Drive Product Demand

The global market is growing as cardiovascular and thromboembolic conditions such as coronary artery disease, peripheral artery disease, deep vein thrombosis, and pulmonary embolism require effective clot-prevention and clot-treatment therapies. As more patients need long-term anticoagulation support, physicians are increasingly using oral Factor Xa inhibitors such as rivaroxaban as they offer convenient fixed-dose treatment compared with traditional anticoagulants. This directly increases prescription demand across hospitals, cardiology clinics, vascular care settings, and retail pharmacies, supporting steady market growth.

• For instance, in May 2025, Lupin received U.S. FDA approval for Rivaroxaban Tablets USP in 10 mg, 15 mg, and 20 mg strengths. These strengths are indicated for stroke and systemic embolism risk reduction in nonvalvular atrial fibrillation, treatment of DVT and PE, reduction in recurrent DVT/PE risk, and prophylaxis of DVT after knee or hip replacement surgery, highlighting the drug’s broad role across cardiovascular and thromboembolic care.

Download Free sample to learn more about this report.

In January 2025, the CDC reported that up to 900,000 people in the U.S. are affected by venous thromboembolism (VTE, a blood clot) each year. Among these, an estimated 60,000–100,000 Americans die of VTE each year.  

Rivaroxaban Market Restraint

Patent Expiry and Generic Competition to Create Price Pressure on Branded Products

The global market is facing restraints as Xarelto has started losing exclusivity in key markets, allowing generic rivaroxaban products to enter the market at lower prices. As generic availability increases, payers and pharmacy benefit managers are more likely to shift prescriptions from branded Xarelto to cheaper alternatives, which reduces branded sales value even when prescription volume remains strong. This creates direct pricing pressure on the originator product and limits overall market value growth, especially in mature markets where generic substitution is faster.

• For instance, in December 2024, the U.K. MHRA issued a Class 2 Medicines Recall for one batch of Xarelto 20 mg film-coated tablets after reports of 15 mg blister strips being found inside packs of 20 mg tablets. The issue is that incorrectly strengthened tablets can create dosing risk in anticoagulation therapy, where underdosing may increase clot risk and incorrect dosing can affect patient safety.

Rivaroxaban Market Opportunity

Expanding Generic Rivaroxaban Availability to Create Growth Opportunities

The global market is expected to gain growth opportunities from the wider availability of generic versions, as lower-priced alternatives can improve patient access and support higher prescription volume in cost-sensitive markets. Since rivaroxaban is used across long-term conditions such as nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism, coronary artery disease, and peripheral artery disease, affordability plays an important role in treatment continuation. As more companies launch multi-strength generic rivaroxaban tablets, pharmacies and payers can shift more patients from branded Xarelto to generic options, which increases volume-based growth even though average selling prices may decline.

• For instance, in May 2025, Alembic Pharmaceuticals announced that it received U.S. FDA final approval for Rivaroxaban Tablets USP in 2.5 mg, 10 mg, 15 mg, and 20 mg strengths. The approved product is therapeutically equivalent to Janssen’s Xarelto and recorded an estimated U.S. market size of USD 445 million for the 2.5 mg strength and USD 8,052 million for the remaining strengths for the year ending March 2025.

Segmentation

Key Insights

The report covers the following key insights:

• Generic Entry and Patent Expiry Impact Analysis
• Pricing and Reimbursement Impact of Generic Rivaroxaban
• Regulatory Scenario, By Key Countries/Regions
• Pricing, Reimbursement, and Market Access Scenario for Specialty RNAi Drugs
• New Product Launches and Indication Expansions, By Key Players
• Key Industry Developments (Mergers, Collaborations, and Acquisitions)

Analysis by Product

Based on product, the global market is segmented into Xarelto and others.

Among these, the Xarelto segment is likely to dominate the market given that it is the original branded rivaroxaban product with long-standing physician familiarity, broad indication coverage, and established use across adult and pediatric anticoagulation care. Even though generic rivaroxaban entry is increasing, Xarelto continues to hold a larger value share as branded pricing remains higher than generics and the product has a strong prescription base across major markets. This makes Xarelto the leading product by revenue, while the “Others” segment is expected to grow faster as generic competition expands.

• For instance, in December 2021, Johnson & Johnson announced that the U.S. FDA approved two new pediatric indications for Xarelto and noted that Xarelto had 11 indications, the most among direct oral anticoagulants at that time. This strengthened the product’s clinical reach and supported its leadership across multiple patient groups.

Analysis by Strength

Based on strength, the market is segmented into 2.5 mg, 10 mg, 15 mg, 20 mg, and 1 mg/mL.

The 20 mg segment is likely to dominate the market as it is widely used for long-term anticoagulation in high-volume adult indications, especially stroke prevention in nonvalvular atrial fibrillation and continued treatment after venous thromboembolism. Since these conditions often require extended or chronic treatment, the 20 mg strength generates repeated prescriptions and higher commercial volume than lower-dose or pediatric-specific strengths. The 10 mg and 15 mg strengths also remain important, but 20 mg has stronger long-term outpatient relevance.

• For instance, in June 2026, Sunshine Biopharma announced the Canadian approval for their rivaroxaban product. This approval was for the 2.5mg, 10mg, 15mg and 20mg variants of the product.

Analysis by Dosage Form

Based on dosage form, the market is segmented into tablets and oral suspension.

The tablets segment is expected to dominate the market given that rivaroxaban is primarily prescribed to adult patients, and most adult indications are served through tablet strengths such as 2.5 mg, 10 mg, 15 mg, and 20 mg. Tablets are easier to dispense through hospital, retail, and online pharmacies, and they are also the main dosage form for generic entry. Oral suspension remains important for pediatric and swallowing-difficulty populations, but its patient base is smaller compared to that of adult tablet users.

• For instance, in August 2025, Indoco Remedies announced final ANDA approval from the U.S. FDA for Rivaroxaban Tablets USP in 2.5 mg, 10 mg, 15 mg, and 20 mg strengths, to market a generic equivalent of Xarelto tablets. This shows that generic competition is concentrated mainly in the tablet dosage form.

Analysis by Type

Based on type, the market is segmented into branded and generic.

The branded rivaroxaban segment is likely to dominate the market as Xarelto still commands higher pricing. It also has a large established prescription base in major markets. As a result, branded products dominate current revenue, while generics are expected to gain share through affordability, payer preference, and pharmacy substitution.

• For instance, in April 2025, Aurobindo Pharma received U.S. FDA final approval for Rivaroxaban Tablets USP, 2.5 mg, as an AB-rated generic equivalent to Xarelto. This highlights the increasing generic entry that is expected to reduce branded share over time gradually.

Analysis by Disease Indication

Based on disease indication, the market is segmented into deep vein thrombosis, pulmonary embolism, coronary artery disease, peripheral artery disease, thromboprophylaxis, and others.

The deep vein thrombosis segment accounted for a major market share. It is one of the core approved uses of rivaroxaban and often requires both initial treatment and continued therapy to reduce the risk of recurrence. Patients diagnosed with DVT need timely anticoagulation to prevent clot progression and reduce the risk of pulmonary embolism, which increases the use of rivaroxaban across hospitals, vascular clinics, and retail pharmacies. The segment also benefits from the availability of 10 mg, 15 mg, and 20 mg tablet strengths, as these strengths support different stages of DVT treatment and long-term clot-prevention therapy.

• For instance, in August 2025, ScieGen Pharmaceuticals received ANDA approval for Rivaroxaban Tablets USP in 2.5 mg, 5 mg, 10 mg, and 20 mg strengths. The approval supported the expansion of generic rivaroxaban availability, including strengths used across thromboembolic treatment settings such as deep vein thrombosis management.

Analysis by Age Group

Based on age group, the market is segmented into pediatric and adult.

The adults segment is expected to lead the market as most rivaroxaban prescriptions are linked to adult cardiovascular and thromboembolic conditions such as DVT, PE, CAD, PAD, and nonvalvular atrial fibrillation. These diseases are more common in adults and older populations, which increases the need for long-term anticoagulant therapy. Pediatric use is FDA-approved and clinically important, but it remains a smaller, specialized segment, mainly supported by oral suspension and weight-based dosing.

• For instance, in March 2025, Lupin announced U.S. FDA approval for Rivaroxaban Tablets USP in 10 mg, 15 mg, and 20 mg strengths and listed adult-heavy indications such as nonvalvular atrial fibrillation, DVT, PE, recurrent DVT/PE risk reduction, and DVT prophylaxis after hip or knee replacement surgery.

Analysis by Distribution Channel

Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies & drug stores, and online pharmacies.

The retail pharmacies and drug stores segment is likely to dominate the market. Rivaroxaban is widely used as an outpatient prescription drug, especially for long-term anticoagulation therapy. Patients treated for chronic clot-prevention needs usually refill prescriptions through retail pharmacies after diagnosis, hospital discharge, or specialist consultation. Hospital pharmacies remain important for treatment initiation and post-surgical use, while online pharmacies are growing but still account for a smaller share in many countries.

• For instance, in May 2025, Camber Pharmaceuticals announced the addition of Rivaroxaban Tablets to its U.S. portfolio. The company launched the product in 2.5 mg, 10 mg, 15 mg, and 20 mg strengths, expanding generic availability across key anticoagulation indications. This is relevant for the rivaroxaban market as the entry of another multi-strength supplier supports broader pharmacy access and increases competition against branded Xarelto.

Regional Analysis

Request for Customization   to gain extensive market insights.

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for approximately 35.0% of the global rivaroxaban market in 2025. The market is growing as the region has a large treated population for various cardiovascular disorders. The U.S. market is also shifting from a mainly branded Xarelto market toward a branded-plus-generic structure after generic approvals started in 2025. This improves affordability, increases payer acceptance, and supports wider prescription access, especially among patients requiring long-term anticoagulation therapy. As more generic strengths become available, prescription volume is expected to rise even though branded product pricing faces pressure.

• For instance, in March 2025, Lupin announced the U.S. launch of Rivaroxaban Tablets USP, 2.5 mg, following final approval from the U.S. FDA. The product is bioequivalent to Xarelto 2.5 mg. It is indicated to reduce the risk of major cardiovascular events in patients with coronary artery disease and major thrombotic vascular events in patients with peripheral artery disease.

The Europe market is expected to grow at a significant CAGR during the forecast period. The regional market growth is mainly driven by broader access, generic penetration, and continued use of oral anticoagulants in cardiovascular and thromboembolic care. Generic competition can expand the treated patient base by reducing therapy costs and improving product availability across cost-sensitive healthcare systems. Since Europe has a high burden of aging-related cardiovascular disease and strong hospital-to-outpatient anticoagulation pathways, the availability of lower-cost rivaroxaban products supports volume-based market expansion.

• For instance, in September 2025, Adalvo announced that it had launched rivaroxaban across Asia, the Middle East, North America, and certain European countries in collaboration with multiple strategic partners. The product was developed based on the reference brand Xarelto, showing how generic rivaroxaban launches are widening access across European and other international markets.

Asia Pacific is expected to grow at a stable CAGR during the forecast period. The Asia Pacific market is growing as countries such as key regions have a rising cardiovascular disease burden, expanding access to oral anticoagulants, and increasing demand for convenient therapies that can be managed outside hospital settings. The region also benefits from strong generic manufacturing capabilities, especially in India, which supports a lower-cost supply for domestic and export markets. As rivaroxaban becomes available across more indications and product formats, its use is expected to increase across adult cardiovascular care and selected pediatric anticoagulation needs.

• For instance, in June 2022, Bayer announced that Japan’s Ministry of Health, Labor and Welfare approved rivaroxaban/Xarelto 2.5 mg twice daily with aspirin for patients with peripheral artery disease after revascularization. This expanded the approved use of rivaroxaban in Japan and supported its adoption in a high-risk cardiovascular patient group in the Asia Pacific.

Key Players Covered

The global rivaroxaban market is moderately fragmented but increasingly consolidating.

The report includes the profiles of the following key players:

• Bayer AG (Germany)
• Johnson & Johnson (U.S.)
• Lupin Limited (India)
• Taro Pharmaceutical Industries Ltd. (Israel)
• Aurobindo Pharma Ltd. (India)
• Alembic Pharmaceuticals Ltd. (India)
• Biocon Pharma Ltd. (India)
• Reddy’s Laboratories Ltd. (India)
• Apotex Corp. (Canada)
• MSN Pharmaceuticals (India)

Key Industry Developments

• August 2025: Sandoz launched generic rivaroxaban in Germany, in new generic strengths of 10 mg, 15 mg, and 20 mg. Rivaroxaban, a Pharma, offers patients in Germany a high-quality, affordable alternative to reference product Xarelto, with a list price advantage across all three strengths.
• June 2024: Adalvo launched Rivaroxaban Film-Coated Tablets in the U.K. Rivaroxaban is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) or with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD).